ALK and non-small cell lung carcinoma: In this setting, case series suggest a high efficacy using effective targeted therapy even after treatment failure of preceding ALK TKIs.24 The prevalence of LMC in NSCLC in general is estimated to range between 3% and 5%25 and substantially increases in molecularly altered subgroups, benefiting from a longer survival due to targeted therapies.